source
- Lilly beats forecasts and raises outlook as Novartis steadies and GSK faces investor pressureLilly reported third‑quarter revenue that exceeded analysts' expectations by about 8%, driven by strong demand for its diabetes and obesity treatments Mounjaro and Zepbound. The company also lifted…
- Corxel to go public via $300 million SPAC merger, advancing GLP-1 pill CX11 and amylin candidateCorxel Pharmaceuticals announced it will become a public company by merging with the SPAC Amanat Acquisition Corp., accompanied by a $300 million private investment. The transaction will fund the…